FDA Approves Darolutamide for Non-metastatic Castration-resistant Prostate Cancer

On July 30, Bayer announced U.S. Food and Drug Administration (FDA) approval of Nubeqa® (darolutamide), an androgen receptor inhibitor (ARi), for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Nubeqa was approved under the FDA's Priority Review designation.

Read corporate press release.

Posted 7/31/2019